IL1A and neoplasm: Specifically, TAS-115 alone and in combination with DOXO significantly reduced the levels of key pro-inflammatory cytokines, including TNF-α, IL-1α, and IL-6, which are often elevated in the TME and contribute to tumor progression, therapy resistance, and immunosuppression.